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Transcriptional activators need to be modulated and eventually switched off after the initial 
event that triggers their activation. Here, we discuss how ubiquitination of activators and 
their proteasome-mediated turnover are crucial steps in this process.Transcriptional activators bind to specific sites in the pro-
moter of target genes and subsequently stimulate various 
events in the transcription cycle. In most cases, activa-
tors are present in an inactive form that is then switched 
on in response to one or more signaling events. These 
triggering mechanisms include posttranslational modifi-
cation of the activator itself (or the proteins that hold it 
in the inactive state), allosteric mechanisms that disrupt 
the interactions between activators and inhibitors, and 
changes in subcellular localization. Although the details 
of these triggering processes are of keen interest to 
biologists, significant attention has only recently been 
focused on how the activity of an activator is limited and 
eventually switched off. Ensuring that ongoing transcrip-
tion of an inducible gene is tied to continued signaling is 
critical to maintaining appropriate homeostasis in cells. 
Therefore, deactivation of activators is presumably also 
a tightly regulated process, but what are the underlying 
mechanisms behind this process?
Transcription-Factor Ubiquitination and Turnover
An obvious mechanism to limit the time that an acti-
vator works is to destroy it via the ubiquitin-protea-
some pathway. Ideally, activator turnover should be 
tied to its ability to drive transcription. Over the last 
few years, evidence has emerged that this is indeed 
the case in some systems (Muratani and Tansey, 
2003). For example, in mammalian cells, the levels of 
proteins that are fused to the Gal4 activation domain 
show an inverse correlation with their potency as 
activators (Molinari et al., 1999). Furthermore, the 
domains of several activators required for turnover via 
the ubiquitin-proteasome pathway (called a degron) 
correspond closely to the activation domains of these 
proteins. Degrons derived from yeast cyclins work as 
transcriptional activation domains when fused to a 
DNA-binding domain. In addition, the F box protein 
Skp2, an E3 ubiquitin ligase, not only regulates the 
stability of Myc in vivo but also acts as a cofactor 
that is essential for full activity of Myc (Muratani and 
Tansey, 2003).Chromatin immunoprecipitation (ChIP) analysis of 
transcription factor-DNA interactions at an estrogen 
receptor α (ER-α)-regulated promoter has yielded valu-
able insights (Reid et al., 2003). These studies confirmed 
previous reports showing that proteasome activity was 
essential for high-level activation of ER-α-regulated 
genes and showed that chemical inhibition of the pro-
teasome resulted in the buildup of polyubiquitinated 
ER-α. Remarkably, ChIP assays revealed that the acti-
vator ER-α (bound to its ligand) cycled on and off the 
promoter with a periodicity of ≈45 min and that various 
other transcription factors—including polymerase com-
ponents, general transcription factors, coactivators, and 
AAA ATPases—also cycled with a periodicity similar to 
ER-α but with a different phase. This is consistent with 
waves of assembly and disassembly of ER-α-dependent 
transcription complexes on the promoter. When protea-
some activity was blocked, this cycling was abrogated. 
These data indicate that proteasome-mediated prote-
olysis is essential for disassembly of transcription com-
plexes during these waves of complex formation and 
dissolution.
What is the mechanistic basis of this coupling between 
activation and proteasome-mediated turnover? The 
answer may lie in the ubiquitination state of the acti-
vator. The first such indication was that deletion of the 
gene encoding the E3 ubiquitin ligase Met30 not only 
increased levels of the artificial activator LexA-VP16 but 
crippled its ability to activate target genes (Salghetti et 
al., 2001). Again, this is consistent with coupled activa-
tion and turnover. This study’s remarkable finding was 
that the introduction of a construct encoding a single 
ubiquitin molecule fused to LexA-VP16 (Ub-LexA-VP16) 
into cultured cells lacking Met30 resulted in significant 
restoration of LexA-responsive reporter-gene transcrip-
tion. Transcription occurs even though the amount of the 
Ub-LexA-VP16 fusion protein remained high, indicating 
that it was not subject to efficient proteolysis. This result 
suggested that activator monoubiquitination is a key 
modification that promotes the activity of the activator. 
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its proteasome-mediated degradation, which requires 
chains of at least four K48-linked ubiquitin molecules 
(Thrower et al., 2000).
Why does monoubiquitination of an activator stimu-
late its activity? This question is only beginning to be 
addressed. A ubiquitination-dependent increase in 
recruitment of P-TEFb, an important elongation factor, 
by LexA-VP16 has been reported (Kurosu and Peterlin, 
2004). The efficiency of posttranscriptional processes 
also may be stimulated by activator ubiquitination 
(Muratani et al., 2005). The effects of activator monou-
biquitination on earlier steps in the gene expression 
cycle are unknown.
Timers and Black Widows
Several investigators have synthesized the available 
data to propose models that intimately link activa-
tor potency, ubiquitination, and proteasome activ-
ity. These have been dubbed “timer” (Conaway et 
al., 2002; Gonzalez et al., 2002) or “black widow” 
(Muratani and Tansey, 2003) mechanisms (see Figure 
1). The timer model assumes that activator monoubiq-
uitination is a necessary licensing event for high-level 
gene expression and that extension of this modifica-
tion into a K48-linked polyubiquitin chain would occur 
subsequently. As stated above, at least four ubiquitin 
molecules must be added to a protein to allow it to 
be recognized as a proteasome substrate (Thrower et 
al., 2000). Therefore, the activator would have the time 
required to go from one to four or more ubiquitins in 
which to drive gene expression, after which it would 
be destroyed by the proteasome.262 Cell 127, October 20, 2006 ©2006 Elsevier Inc.The black widow model also pro-
poses a window of activity but specifi-
cally suggests that activator polyubiq-
uitination and subsequent destruction 
is a necessary consequence of “mat-
ing” with the polymerase holoenzyme. 
Figure 1. Modulating the Activity of 
 Transcriptional Activators
Two models for understanding the role of post-
translational modifications and proteasome-me-
diated degradation of activators in regulating 
their activity are shown. In the “black widow” 
model, recruitment of the transcription complex 
(PIC, preinitiation complex) to the promoter re-
sults in the phosphorylation and ubiquitination of 
the activator. These modifications, which even-
tually trigger activator destruction, are contained 
within the transcription complex. The second-
generation timer model is a modification of the 
timer and black widow models. For clarity, only 
the activator is shown. In this model, it is pro-
posed that only the monoubiquitinated form of 
the activator is competent to drive transcription. 
The ubiquitinated state of the activator is con-
trolled by ubiquitin ligases and deubiquitinases 
and potentially by kinases and phosphatases. 
See text for details.This model incorporates the findings 
of an elegant study on the turnover of the yeast activa-
tor Gcn4 (Chi et al., 2001), in which it was shown that 
the Srb10 kinase phosphorylates Gcn4 and that this 
triggers subsequent polyubiquitination by the ubiquitin 
ligase complex SCFCdc4. It is often the case that phos-
phorylation triggers subsequent ubiquitination. Srb10 is 
a component of the Mediator complex that associates 
with the C-terminal domain of the largest subunit of RNA 
polymerase II. Thus, by carrying out a central function 
of an activator (the recruitment of the Mediator complex 
and hence RNA polymerase II), Gcn4 is presented to the 
protein kinase that triggers its destruction.
An interesting consequence of the observed require-
ment for proteasome-mediated turnover of at least 
some activators in the context of these models is that 
one is forced to speculate that the polyubiquitinated 
protein is much less active than the monoubiquitinated 
form. Otherwise, in the absence of proteolysis, the 
polyubiquitinated form of the activator would simply 
build up over time, and gene expression would continue 
unabated. As this is not the case, it might be that, when 
the activator (or perhaps some other transcription pro-
tein) is polyubiquitinated, it loses activity and, unless 
cleared by the proteasome, “gums up the works.” Why 
a polyubiquitinated activator would be less active than 
the monoubiquitinated form is unknown, but the impor-
tant point is that, rather than being essential for activa-
tion per se, proteasome-mediated degradation may be 
required to eliminate an “exhausted” form of the activa-
tor that would otherwise act as a competitive inhibitor 
of fresh activator. This viewpoint may help to resolve 
some of the apparent contradictions to the intimate 
connection of transcription and proteasome-mediated 
proteolysis discussed below.
The timer and black widow models are immensely 
appealing in providing a mechanism to couple the licens-
ing of a transcriptional activator through monoubiquitina-
tion, which may be preceded by phosphorylation, to its 
subsequent destruction. Nonetheless, there are already 
data in the literature that argue that this mechanism is 
not general for all inducible activators. For example, the 
glucocorticoid receptor does not require proteasome 
activity to drive gene expression and is an extremely 
long-lived protein that must be deactivated by nonpro-
teolytic mechanisms (Hager et al., 2004). The activity 
of the heat-shock factor (HSF) is strongly stimulated by 
proteasome inhibition and, moreover, HSF forms long-
lived complexes on native promoters that do not cycle in 
an ER-α-like fashion (Yao et al., 2006). A recent report 
using a novel variant of the chromatin precipitation assay 
capable of monitoring the lifetime of activator-promoter 
complexes argues that this is also true for the yeast acti-
vator Gal4 (Nalley et al., 2006), though there are conflict-
ing reports (Lipford et al., 2005; Muratani et al., 2005). 
Even in the case of ER-α, mutations at a single residue 
(S118) can uncouple activator potency and proteasome-
mediated turnover, showing that these are mechanisti-
cally separable functions (Valley et al., 2005).
A Second-Generation Timer Model
Is it possible to reconcile all of the apparently dispa-
rate findings described above into a cohesive model 
for regulating activator potency and the longevity of 
activator-promoter complexes? Although the answer 
is not clear, the second-generation timer model shown 
in Figure 1 attempts to do so. This model focuses on 
the monoubiquitinated (and probably phosphorylated) 
activator as the intermediate of central importance 
and acknowledges the fact that monoubiquitination 
and subsequent extension into a polyubiquitin chain 
are two completely different chemical events. These 
events can occur at different rates or even be mediated 
by different ubiquitin ligases, with the chain extenders 
sometimes referred to as E4 ligases. Furthermore, deu-
biquitinases (DUBs) are invoked as a potential mecha-
nism to antagonize chain growth or even to reverse the 
monoubiquitination event. Finally, as mentioned above, 
it assumes that the polyubiquitinated activator is poorly 
active for reasons unknown.
In this view, if chain extension is efficient, the active 
period for the licensed (monoubiquitinated) activator 
would be short and proteasome activity would be critical 
to remove the inactive, polyubiquitinated molecule from 
the system and open the promoter to “fresh” transcrip-
tion factor. However, if chain extension were slow due 
to poor activity of an E4 ligase or potent antagonism of 
extension by a DUB, the licensed activator could function 
for a considerable period of time, the activator-promoter 
complex would be long lived, and proteasome activity 
would be less important. Given that different E3 and E4 ligases and DUBs presumably work on different tran-
scriptional activators, it seems reasonable to assume 
that the relative rates of these events can vary widely 
for different activators. Furthermore, as these modifying 
enzymes must bind to their substrates, it suggests how 
specific mutations in the activator could easily alter the 
relative rates of mono- and polyubiquitination or DUB-
catalyzed chain shortening, thus apparently uncoupling 
activation potency and proteasome-mediated turnover, 
as was observed for mutations at S118 in ER-α. Finally, 
invoking the activity of DUBs (and probably also phos-
phatases) in the regulation of activator potency provides 
a simple mechanism for shutting off a transcriptional 
switch completely without the requirement for activator 
proteolysis.
Clearly, this model raises as many questions as it 
answers. What are the relative rates of mono- and poly-
ubiquitination for a given activator, and how are they 
regulated? Do these events even involve the same lysine 
residue? Do DUBs indeed recognize ubiquitinated acti-
vators as substrates? If so, how are opposing E3 or E4 
ubiquitin ligases and DUB activities balanced? How can 
we more efficiently match activators with the modifying 
enzymes that operate on them? Why would a monou-
biquitinated activator be more potent than one bearing a 
polyubiquitin chain? Nevertheless, it may provide a use-
ful framework for developing experiments to probe these 
complex systems.
The Tortoise and the Hare
A final point that is highly relevant to thinking about the 
dynamics of transcription-factor function is that the rela-
tively slow cycling events of the type reported for ER-α 
transcription complexes (t1/2 ≈ 45 min) may be overlaid on 
top of far more rapid activator-promoter association and 
dissociation events. A highly expressed gene fires once 
every few seconds. Do activator-promoter complexes sur-
vive multiple rounds of transcription, or do they dissociate 
after every round (or even more frequently)? Techniques 
such as standard ChIP analysis, DNase I footprinting, 
and the like provide a time-averaged view of DNA-protein 
interactions and would not be expected to reveal rapid, 
reversible association and dissociation. Fluorescence 
recovery after photobleaching (FRAP) is a useful tech-
nique to probe rapid equilibria. In this experiment, one 
employs cells that express a large amount of an activa-
tor-GFP fusion protein and contain an artificial promoter 
containing hundreds of activator binding sites. When the 
fluorescently tagged activator binds to these sites, it cre-
ates a microscopically observable fluorescent dot. When 
irradiated with a focused, high-powered laser beam, the 
GFP chromophores in this dot can be photobleached 
rapidly without affecting fusion protein elsewhere in the 
cell. One can then watch how long it takes for the dot to 
be reformed, which is a reflection of the amount of time 
required for the bleached fusion protein to dissociate and 
be replaced by fluorescent molecules from the large pool 
of unbound activator-GFP fusion protein.Cell 127, October 20, 2006 ©2006 Elsevier Inc. 263
Studies of GFP fusions of the glucocorticoid recep-
tor by this technique have revealed highly dynamic 
activator-DNA complexes with a half-life of a few sec-
onds, which is on the order of the frequency of the rate 
of gene transcription (Hager et al., 2004). If this mea-
surement truly reflects the kinetic stability of the acti-
vator-DNA complexes in cells, it suggests that they 
are being actively dissociated by chaperones (Free-
man and Yamamoto, 2002) or chromatin-remodeling 
complexes (Hager et al., 2004) because the intrinsic 
dissociation rates of the protein-DNA complexes are 
much longer.
It is fair to ask whether these short timescale 
dynamics really matter in the larger picture of regulat-
ing gene expression. Put another way, how long must 
an activator remain resident on a promoter to drive 
transcription, and, if this time is increased, does it 
lead to more potent activation? The jury is still out on 
this point, but a recent study by Setzer and colleagues 
(Brady et al., 2005) suggests that the answer to the 
second question might be yes. In a study of different 
mutations of the RNA polymerase III activator TFIIIA 
that affected the stability of the protein-DNA com-
plex, they found that the ability of the mutant proteins 
to activate transcription in yeast correlated with the 
kinetic dissociation constant rather than the equilib-
rium binding constant.
Finally, it is important to remember that not all acti-
vator-promoter complexes are so dynamic. As men-
tioned above, there is clear evidence for stable activa-
tor-promoter complexes such as those formed by HSF 
(Yao et al., 2006) or Gal4 (Nalley et al., 2006), which 
apparently are not subject to, or can resist, this con-
stant antagonism.
Conclusion
In conclusion, there has been an explosion of interest 
in the mechanisms employed to keep activators under 
control once they are induced. The data currently avail-
able suggest that both rapid (timescale of seconds) and 
slower (timescale of many minutes) mechanisms that 
modulate the stability of promoter-bound transcription 
complexes exist. Some of these mechanisms clearly 
involve the proteasome; some do not and instead are 
the result of active remodeling by ATP-dependent pro-
teins. Different activators employ these various mecha-
nisms to different extents, leading to a wide spectrum 
of dynamic behaviors of activator-promoter complexes 
within cells. Deciphering how all of these different 
processes are regulated and balanced is clearly criti-264 Cell 127, October 20, 2006 ©2006 Elsevier Inc.cal to understanding the process of gene expression 
and should provide an interesting challenge for years 
to come.
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